AUTHORS
Joseph Chiaramida, MS, NP, RN, Eric Matthew Jurgens, MD2, Maria Lia Palomba, MD3, Gunjan L. Shah, MD, MS4, Sergio Giralt, MD5, Saad Z. Usmani, MD6, Jae H Park, MD7, Sham Mailankody, MBBS8
AFFILIATIONS
1 Memorial Sloan Kettering Cancer Center, NEW YORK, New York, United States
2 Memorial Sloan Kettering Cancer Center, NEW YORK, New York, United States
3 Memorial Sloan Kettering Cancer Center, NEW YORK, New York, United States
4 Memorial Sloan Kettering Cancer Center, NEW YORK, New York, United States
5 Memorial Sloan Kettering Cancer Center, NEW YORK, New York, United States
6 Memorial Sloan Kettering Cancer Center, NEW YORK, New York, United States
7 Memorial Sloan Kettering Cancer Center, NEW YORK, New York, United States
8 Memorial Sloan Kettering Cancer Center, NEW YORK, New York, United States
ABSTRACT
Introduction
CAR T-cell therapy has transformed the prognosis for patients diagnosed with hematologic malignancies throughout the continental United States, but many of them face geographic access barriers. Apheresis requires coordination between three geographically discordant stakeholders: the patient, the apheresis center, and the manufacturing company. Toxicity management requires either lengthy hospitalizations, or proximity monitoring and a caregiver. As international demand increases and investment into CAR T supply chains intensifies, we recognize that early quantification of patient access and coordination between stakeholders will ultimately enable more patients throughout the country to receive this potentially curative therapy. We quantified the landscape of driving distances and travel times to CAR T centers in the continental United States to identify gaps in access and to estimate the number of patients that already live within the commonly applied 1 hour proximity threshold to a CAR T center.
Methods
We compiled a list of CAR T centers from BMT InfoNet (accessed June 30, 2026); 161 treated lymphoma and 163 treated multiple myeloma. We geocoded their addresses to latitude/longitude coordinates and then loaded 2020 Census tract centroids of all 83,777 continental-U.S. tracts from the 2025 Census Gazetteer. We measured the driving distance in miles and travel times in minutes between every Census tract centroid and every CAR T center using Open Source Routing Machine (OSRM). Then we used demographic data from ACS 5-year 2023 adult (≥18) population (256.98M) to model stratification by rural/urban status, Census region, tract median household income quintile, and tract racial/ethnic composition. We report population-weighted median distances and travel times.
Results
Among continental U.S. adults (N=256.98M), 163M (63.3%) lived within 1 hour of a lymphoma CAR T center. Median travel distance was 26.1 mi, corresponding to a median travel time of 39.4 min. Measured by distance, 58.4% of urban population vs. 7.5% of rural population lived within 25 miles of a lymphoma CAR T center. Measured by travel time : 72.7% of urban patients vs. 22.8% of rural patients lived within 60 min. The Northeast (78.5%) and West (67.4%) served a larger percentage of population seeking lymphoma therapy within 60 min, while the South (57.4%) and Midwest (56.8%) served a smaller percentage. There was a positive relationship between census tract income quintile and percent of population that lived within 60 min. For lymphoma-enabled centers, 87.6% of population in the highest income quintile lived within 60 min vs. 48.2% in the lowest income quintile. Stratification by census tract race/ethnicity composition showed lymphoma geographic access was greatest for tracts in which over 25% of the population identified as NH Asian (98.1% ≤ 60 min) and poorest for tracts in which over 75% of the population identified as NH White (46.3% ≤ 60 min), largely following the urban/rural distribution. Access to myeloma-enabled centers was nearly identical to lymphoma across all measures (median 25.8 mi, 39.1 min; 63.4% within 60 min), reflecting near-complete overlap between the centers offering each product.
Conclusions
Approximately 63% of U.S. adults live within 1 hour travel time to a CAR T center. However, access remains largely inequitable based on urban/rural status, region, and income quintile. These findings support geographically targeted center expansion and improved travel/lodging support. While closer-to-home-delivery methods (e.g. off-the-shelf or allo CAR T) offer the potential to shorten treatment times and lower costs, they cannot resolve the requirement for proximity monitoring. Limitations include reliance on a public directory; racial/ethnic strata reflect neighborhood composition and do not account for racial differences in disease prevalence; travel times assume no traffic and do not consider alternative modes of transportation.
DISCLOSURES
Joseph Chiaramida, MS, NP, RN: No relevant conflicts of interest to declare.